Hu5F9-G4: Phase I data

Data from 16 patients with solid tumors in a 2-part, open-label, dose-escalation U.S. Phase I trial showed that doses of up to once-weekly 3 mg/kg Hu5F9-G4 with a 1 mg/kg priming dose were well tolera...